[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pregnant-individuals\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pregnant-individuals":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100650184","gestational-response-outcomes-and-weight-after-glp-1-use-100650184",false,"NCT07743567","Gestational Response, Outcomes, and Weight After GLP-1 Use","GROW","Inclusion Criteria:\n\n* Adult women\n* Less than or equal to 20 weeks gestation at first visit\n* English speaking\n\nExclusion Criteria:\n\n* \\\u003C18 years at time of initial visit\n* Type 2 diabetes\n* History of bariatric surgery\n* Multiple gestation\n* Cannot consent for themselves\n* Cannot read and speak English\n* Incarcerated",true,"FEMALE","18 Years","45 Years",{"count":21,"type":22},400,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn if using GLP-1RA medications for weight loss before pregnancy influences gestational weight gain and pregnancy outcomes. The main aims of the study are to:\n\n* Compare gestational weight gain between women with preconception GLP-1RA exposure and those without exposure.\n* Compare obstetrical outcomes between women with preconception GLP-1RA exposure and those without exposure.\n\nResearchers will compare pregnant women with a history of GLP-1RA use to pregnant women who have not used a GLP-1RA to compare differences.\n\nParticipants will be asked to complete questionnaires at multiple timepoints during and after pregnancy that ask questions about medication history, thoughts and feelings around food, etc.",[26,27,28],"Pregnant Individuals","Obesity & Overweight","Gestational Weight Gain",[30,31,32,33,34,35,36],"Glucagon-like peptide 1 receptor agonist","Pregnancy","Gestational weight gain","Maternal obesity","Pregnancy outcomes","Food noise","Preconception","RECRUITING","2026-07-30",{"date":40,"type":41},"2026-08-04","ACTUAL",{"date":43,"type":41},"2026-04-13",{"date":45,"type":22},"2028-04",{"name":47,"class":48},"University of Kansas Medical Center","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":60,"conditions":61,"keywords":68,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100642613","the-advance-assay-development-and-validation-for-pre-natal-and-obstetric-conditions-study-is-the-largest-us-based-prospective-study-demonstrating-a-circulating-fetal-cell-cfc-based-approach-to-non-invasive-fetal-risk-assessment-100642613","NCT07643896","The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment","ADVANCE Study: Assay Development and Validation for Pre-Natal and Obstetric Conditions","ADVANCE","Inclusion Criteria:\n\n* pregnant individuals between 10 and 20 weeks of gestation\n* singleton gestation\n\nExclusion Criteria:\n\n\\- active cancer",{"count":59,"type":22},1000,"The goal of the ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) study is to compare the concordance of results of a novel non-invasive circulating fetal cell (CFC) assay to the results of prenatal invasive diagnostic testing or postnatal genetic and clinical diagnosis of the resulting neonate. This is a prospective study of pregnant individuals.",[26,62,63,64,65,66,67],"Aneuploidy","Down Syndrome (Trisomy 21)","22q11.2 Deletion Syndrome","Trisomy 13","Trisomy 18","Sex Chromosome Abnormalities",[69,70,71,72,73],"pregnant","aneuploidy","NIPT","NIPS","circulating fetal cell","2026-06-10",{"date":76,"type":41},"2026-06-12",{"date":78,"type":41},"2026-01-10",{"date":80,"type":22},"2028-06",{"name":82,"class":83},"BillionToOne Inc.","INDUSTRY",6]